Envestnet Portfolio Solutions Inc. Has $721,000 Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Envestnet Portfolio Solutions Inc. trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 35.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,292 shares of the biopharmaceutical company's stock after selling 6,143 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Halozyme Therapeutics were worth $721,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. CBIZ Investment Advisory Services LLC acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $29,000. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $29,000. Smartleaf Asset Management LLC lifted its position in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 197 shares during the last quarter. UMB Bank n.a. lifted its position in shares of Halozyme Therapeutics by 267.4% in the first quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company's stock valued at $84,000 after buying an additional 960 shares during the last quarter. Finally, Parkside Financial Bank & Trust lifted its position in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 322 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

HALO opened at $52.32 on Thursday. The business has a fifty day simple moving average of $56.28 and a 200 day simple moving average of $56.34. The company has a market capitalization of $6.45 billion, a PE ratio of 13.91, a price-to-earnings-growth ratio of 0.36 and a beta of 1.19. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $70.51. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.13. The firm had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The company's quarterly revenue was up 35.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.79 EPS. Research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 4,497 shares of the business's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the transaction, the director now owns 28,611 shares of the company's stock, valued at approximately $1,727,246.07. The trade was a 13.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $52.96, for a total value of $1,059,200.00. Following the transaction, the chief executive officer now directly owns 733,719 shares of the company's stock, valued at $38,857,758.24. This trade represents a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold 45,000 shares of company stock valued at $2,437,501 in the last three months. Corporate insiders own 2.40% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on HALO. HC Wainwright reaffirmed a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, May 29th. Benchmark lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Morgan Stanley downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and reduced their price target for the company from $73.00 to $62.00 in a research note on Wednesday, May 14th. Leerink Partners downgraded Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a research note on Tuesday, May 13th. Finally, JPMorgan Chase & Co. boosted their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of "Hold" and a consensus target price of $61.90.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.